A Phase 2 Study of PTG-300 in Non-Transfusion Dependent (NTD) and Transfusion-Dependent (TD) β-Thalassemia Subjects With Chronic Anemia
Phase of Trial: Phase II
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs PTG 300 (Primary)
- Indications Beta-thalassaemia
- Focus Proof of concept; Therapeutic Use
- Acronyms TRANSCEND
- Sponsors Protagonist Therapeutics
- 03 Dec 2019 According to a Protagonist Therapeutics media release, detailed results with dditional dose regimens and longer follow-up, with clinical efficacy are expected in 2020.
- 03 Dec 2019 Results published in the Protagonist Therapeutics Media Release
- 08 Aug 2019 Planned number of patients changed from 84 to 192.